Study develops a novel intranasal influenza virus-vectored vaccine for SARS-CoV-2
Researchers developed a novel intranasal vaccine candidate for coronavirus disease 2019 (COVID-19).
Stay updated with breaking news from Structural Protein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers developed a novel intranasal vaccine candidate for coronavirus disease 2019 (COVID-19).
A recent study identified inhibitors for SARS-CoV-2 non-structural protein 14 (Nsp14).
Researchers uncovered a novel mechanism that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses (CoVs) use to exploit host antiviral immune system to facilitate their replication.
With the continuous emergence of new variants and the risk of new strains of the virus, the development of innovative therapies against SARS-CoV-2 remains a major public health challenge.
In a new study, researchers investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope (E) protein activity in terms of calcium cations (Ca2+) cations.